CL2010000790A1 - Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03). - Google Patents

Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03).

Info

Publication number
CL2010000790A1
CL2010000790A1 CL2010000790A CL2010000790A CL2010000790A1 CL 2010000790 A1 CL2010000790 A1 CL 2010000790A1 CL 2010000790 A CL2010000790 A CL 2010000790A CL 2010000790 A CL2010000790 A CL 2010000790A CL 2010000790 A1 CL2010000790 A1 CL 2010000790A1
Authority
CL
Chile
Prior art keywords
hybridoma
beta6
div
psoriasis
sol
Prior art date
Application number
CL2010000790A
Other languages
English (en)
Inventor
Sheppard Dean
M Violette Shelia
H Weinreb Paul
J Simon Kenneth
R Leone Diane
Original Assignee
Biogen Idec Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29586753&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010000790(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc, Univ California filed Critical Biogen Idec Inc
Publication of CL2010000790A1 publication Critical patent/CL2010000790A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Anticuerpo monoclonal que se une a integrina alfa-nu-beta-6 producido por el hibridoma atcc pta-3848, que comprende los cdr1, cdr2 y cdr3 de las cadenas pesada y liviana; hibridoma que lo secreta; composición farmacéutica que lo comprende; y su uso para tratar enfermedades mediadas por la integrina alfa-nu-beta-6.
CL2010000790A 2002-03-13 2010-07-23 Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03). CL2010000790A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36499102P 2002-03-13 2002-03-13
US42628602P 2002-11-13 2002-11-13

Publications (1)

Publication Number Publication Date
CL2010000790A1 true CL2010000790A1 (es) 2011-02-18

Family

ID=29586753

Family Applications (8)

Application Number Title Priority Date Filing Date
CL2010000788A CL2010000788A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03).
CL2010000789A CL2010000789A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal anti integrina alfabeta6, que inhibe la union de alfav-beta-6al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; uso para deteccion de alfa-vbetas; hibridoma con n° de acceso atcc pta-3646 (div.sol.no. 513-03)
CL2010000792A CL2010000792A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal que se une a integrina alfavbeta6 o fragmento que enlaza a antigeno que comprende los mismos cdr que un anticuerpo producido por el hibridoma 7.1c5 (numero de acceso atcc pta-3900); composicion farmaceutica que lo comprende; hibridoma; y su uso (div.sol.no.513-03).
CL2010000785A CL2010000785A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; hibridoma (atcc pta-3645); metodo in vitro para inhibir el crecimiento de una celula cancerigena (divisional de la solicitud n° 513-03).
CL2010000787A CL2010000787A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal que se une a integrina alfa-v-beta-6 (atcc pta-3896); composicion farmaceutica que lo comprende; hibridoma que lo produce; util para tratar enfermedades mediadas por dicha integrina como fibrosis, psoriasis, cancer y otros trastornos. (divisional solicitud n° 513-03)
CL2010000786A CL2010000786A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal anti integrina alfavbeta6 que inhibe la union de alfavbeta6 al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; método in vitro y hibridoma con nº de acceso atcc pta-3647. (divisional sol.513-03)
CL2010000791A CL2010000791A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03)
CL2010000790A CL2010000790A1 (es) 2002-03-13 2010-07-23 Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03).

Family Applications Before (7)

Application Number Title Priority Date Filing Date
CL2010000788A CL2010000788A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03).
CL2010000789A CL2010000789A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal anti integrina alfabeta6, que inhibe la union de alfav-beta-6al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; uso para deteccion de alfa-vbetas; hibridoma con n° de acceso atcc pta-3646 (div.sol.no. 513-03)
CL2010000792A CL2010000792A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal que se une a integrina alfavbeta6 o fragmento que enlaza a antigeno que comprende los mismos cdr que un anticuerpo producido por el hibridoma 7.1c5 (numero de acceso atcc pta-3900); composicion farmaceutica que lo comprende; hibridoma; y su uso (div.sol.no.513-03).
CL2010000785A CL2010000785A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; hibridoma (atcc pta-3645); metodo in vitro para inhibir el crecimiento de una celula cancerigena (divisional de la solicitud n° 513-03).
CL2010000787A CL2010000787A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal que se une a integrina alfa-v-beta-6 (atcc pta-3896); composicion farmaceutica que lo comprende; hibridoma que lo produce; util para tratar enfermedades mediadas por dicha integrina como fibrosis, psoriasis, cancer y otros trastornos. (divisional solicitud n° 513-03)
CL2010000786A CL2010000786A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonal anti integrina alfavbeta6 que inhibe la union de alfavbeta6 al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; método in vitro y hibridoma con nº de acceso atcc pta-3647. (divisional sol.513-03)
CL2010000791A CL2010000791A1 (es) 2002-03-13 2010-07-23 Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03)

Country Status (23)

Country Link
US (4) US7465449B2 (es)
EP (4) EP2287198A3 (es)
JP (6) JP4473117B2 (es)
KR (1) KR101098109B1 (es)
CN (4) CN1646160A (es)
AR (1) AR038970A1 (es)
AU (1) AU2003261071C1 (es)
BR (1) BRPI0308585B8 (es)
CA (1) CA2478833C (es)
CL (8) CL2010000788A1 (es)
EA (1) EA011853B1 (es)
ES (1) ES2389037T3 (es)
HK (2) HK1074381A1 (es)
IL (4) IL164021A0 (es)
IS (1) IS7443A (es)
ME (1) ME00804B (es)
MX (1) MXPA04008870A (es)
MY (2) MY147019A (es)
NO (1) NO334834B1 (es)
NZ (2) NZ535425A (es)
PL (1) PL216223B1 (es)
RS (1) RS52488B (es)
WO (1) WO2003100033A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00804B (me) * 2002-03-13 2012-03-20 Biogen Idec Inc Anti-alpha v beta 6 antitela
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
AU2012258386B2 (en) * 2005-07-08 2014-08-07 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US20100267060A1 (en) * 2006-01-17 2010-10-21 Biosite Incorporated High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis
EP2046374A4 (en) 2006-07-10 2010-05-05 Biogen Idec Inc COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS
AU2007348941B2 (en) * 2006-08-03 2011-08-04 Medimmune Limited Antibodies directed to alphaVbeta6 and uses thereof
CA2665885A1 (en) * 2006-10-19 2008-12-04 The Regents Of The University Of California Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6
LT2164992T (lt) * 2007-05-30 2016-09-12 Lpath, Inc. Lizofosfatido rūgšties kompozicijos ir prisirišimo būdai
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
ES2639016T3 (es) * 2007-11-16 2017-10-25 The Rockefeller University Anticuerpos específicos para la forma protofibrilar de proteína beta-amiloide
BRPI0912570B8 (pt) 2008-05-07 2021-05-25 Argos Therapeutics Inc anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos
AU2009245724A1 (en) * 2008-05-09 2009-11-12 Ablynx N.V. Amino acid sequences directed against integrins and uses thereof
CA2724231A1 (en) 2008-05-15 2009-11-19 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
WO2011020529A2 (en) * 2009-08-19 2011-02-24 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
WO2011119524A1 (en) * 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
BR112012027900A2 (pt) 2010-04-30 2020-05-12 Alexion Pharmaceuticals, Inc. Anticorpos anti-c5a e métodos para usar os anticorpos
WO2012143495A2 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
CN104220094A (zh) * 2012-02-17 2014-12-17 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
DK2900265T3 (en) 2012-09-27 2018-08-20 Biocare Medical Llc Anti-Uroplakin II Antibodies, Systems and Methods
PT2905335T (pt) * 2012-10-03 2018-03-12 Chiome Bioscience Inc Anticorpo anti-hdlk-1 tendo uma atividade anti-tumoral in vivo
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
EP2962113B1 (en) 2013-02-28 2019-04-03 Biocare Medical, LLC Anti-p40 antibodies systems and methods
KR102066319B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
WO2014144466A1 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
RU2725825C2 (ru) 2013-08-30 2020-07-06 Иммьюноджен Инк. Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1
KR102150616B1 (ko) 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
JP6527508B2 (ja) * 2013-10-01 2019-06-05 メディミューン リミテッド αＶβ６を過剰発現する癌を治療及び診断する方法
WO2015051320A2 (en) 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
CN104721225A (zh) 2013-12-19 2015-06-24 高露洁-棕榄公司 口腔护理组合物
EP3086814B1 (de) 2013-12-23 2020-06-24 Bayer Pharma Aktiengesellschaft Binder-konjugate (adcs) mit ksp-inhibitoren
CA2938129A1 (en) * 2014-02-03 2015-08-06 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN107921288A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂的靶向缀合物
CN108135986B (zh) * 2015-08-13 2022-07-29 纽约大学 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
EP3432934B1 (de) 2016-03-24 2022-02-23 Bayer Pharma Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
US20190284259A1 (en) * 2016-07-22 2019-09-19 Georgia State University Research Foundation Monoclonal Antibodies to B Virus And Their Use For Identification Of B Virus Specific Reactive Peptides
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
KR102486434B1 (ko) 2016-11-08 2023-01-09 리아타 파마슈티컬즈 홀딩스, 엘엘씨 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
CA3044526A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN116712540A (zh) 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
IL310558A (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
CN110312533B (zh) 2016-12-21 2023-11-03 拜耳公司 具有酶促可裂解的基团的细胞毒性活性剂的前药
GB201720989D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
MX2020012034A (es) 2018-05-11 2021-04-12 Glaxosmithkline Ip Dev Ltd Inhibidores de furina.
US20220111065A1 (en) 2018-05-23 2022-04-14 Adc Therapeutics Sa Molecular adjuvant
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB201908536D0 (en) 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
WO2021108302A1 (en) * 2019-11-26 2021-06-03 Children's Hospital Medical Center Cela-1 inhibition for treatment of lung disease
CN114828887A (zh) 2019-12-05 2022-07-29 思进公司 抗-αVβ6抗体和抗体-药物偶联物
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
CN117396508A (zh) * 2021-01-26 2024-01-12 加利福尼亚大学董事会 用于治疗和预防与avb8整合素相关的疾病的组合物和方法
JP2024506291A (ja) 2021-02-03 2024-02-13 ビーピー アセット ヴイ，インコーポレーテッド 吸入用のフューリンインヒビターの製剤
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6417324B1 (en) * 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
US5688960A (en) 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5795894A (en) 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU6773596A (en) 1995-08-17 1997-03-12 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
EP1916300A1 (en) 1995-08-29 2008-04-30 Kirin Pharma Kabushiki Kaisha Chimeric animal and method for producing the same
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
ATE248192T1 (de) * 1996-06-07 2003-09-15 Neorx Corp HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
AU6721696A (en) 1996-07-15 1998-03-06 Human Genome Sciences, Inc. Cd44-like protein
US5789422A (en) 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5783579A (en) 1996-12-20 1998-07-21 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
NZ515955A (en) * 1997-08-08 2003-04-29 Univ California Hybridoma producing a monoclonal antibody against beta-6 integrin
PL341569A1 (en) 1998-01-23 2001-04-23 Merck Patent Gmbh Monoclonal anti-alphav-integrin antibody and application thereof as an inhibitore of alphavbeta6-integrin to fibronectin bond
JP2002533064A (ja) 1998-12-19 2002-10-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング インテグリンαｖβ６阻害剤
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10063173A1 (de) 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
PL367324A1 (en) 2001-04-13 2005-02-21 Biogen, Inc. Antibodies to vla-1
DE10118550A1 (de) 2001-04-14 2002-10-17 Merck Patent Gmbh Liganden des Integrins alpha¶nu¶beta¶6¶
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
EP2289941A3 (en) 2002-02-25 2012-01-18 Elan Pharmaceuticals Inc. Administration of agents for the treatment of inflammation
ME00804B (me) 2002-03-13 2012-03-20 Biogen Idec Inc Anti-alpha v beta 6 antitela
US20040048312A1 (en) 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
WO2003097615A1 (en) 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
JP4741242B2 (ja) 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
CA2540730C (en) 2003-10-01 2012-08-21 Merck Patent Gmbh Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
US20070292887A1 (en) 2003-11-04 2007-12-20 Bayer Pharmaceuticals Corporation Immunohistochemical Methods
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
EP2046374A4 (en) 2006-07-10 2010-05-05 Biogen Idec Inc COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS
CA2665885A1 (en) 2006-10-19 2008-12-04 The Regents Of The University Of California Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6
GB0803192D0 (en) 2008-02-22 2008-04-02 Mubio Products Bv SCLC biomarker panel
PL2368118T3 (pl) 2008-12-23 2014-03-31 Merck Patent Gmbh Biomarkery dla inhibitorów z aktywnością antyangiogeniczną
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
ES2875535T3 (es) 2012-03-29 2021-11-10 Biogen Ma Inc Biomarcadores para su uso en aplicaciones de terapia de integrina

Also Published As

Publication number Publication date
EP2336185A1 (en) 2011-06-22
EA200401198A1 (ru) 2005-04-28
ME00804B (me) 2012-03-20
EP2287199A3 (en) 2011-05-25
NZ563951A (en) 2009-04-30
ES2389037T3 (es) 2012-10-22
NZ535425A (en) 2008-05-30
CN1646160A (zh) 2005-07-27
CN104805090A (zh) 2015-07-29
MXPA04008870A (es) 2005-06-17
CL2010000788A1 (es) 2011-02-18
CA2478833A1 (en) 2003-12-04
KR101098109B1 (ko) 2011-12-26
JP2005528099A (ja) 2005-09-22
EP2287198A3 (en) 2011-05-25
WO2003100033A2 (en) 2003-12-04
EP1490110A2 (en) 2004-12-29
CL2010000791A1 (es) 2011-02-18
CN102924598A (zh) 2013-02-13
BRPI0308585B8 (pt) 2021-05-25
MY147019A (en) 2012-10-15
EP1490110A4 (en) 2006-12-27
PL216223B1 (pl) 2014-03-31
JP2015126743A (ja) 2015-07-09
CN102924598B (zh) 2014-12-31
NO20044347L (no) 2004-12-13
JP4473117B2 (ja) 2010-06-02
EP2287198A2 (en) 2011-02-23
AU2003261071C1 (en) 2008-12-11
EP1490110B1 (en) 2012-06-13
CL2010000785A1 (es) 2011-02-18
US20120251532A1 (en) 2012-10-04
AU2003261071A1 (en) 2003-12-12
HK1074381A1 (en) 2005-11-11
HK1213007A1 (zh) 2016-06-24
CL2010000787A1 (es) 2011-02-11
IL164021A0 (en) 2005-12-18
US20090186036A1 (en) 2009-07-23
JP2012228269A (ja) 2012-11-22
IL225633A0 (en) 2014-03-31
AR038970A1 (es) 2005-02-02
CN102659946A (zh) 2012-09-12
PL372662A1 (en) 2005-07-25
CL2010000789A1 (es) 2011-02-18
JP2015091807A (ja) 2015-05-14
IL164021A (en) 2013-04-30
AU2003261071B2 (en) 2008-05-15
JP5616932B2 (ja) 2014-10-29
CL2010000792A1 (es) 2011-02-18
BR0308585A (pt) 2005-02-01
NO334834B1 (no) 2014-06-16
BRPI0308585B1 (pt) 2019-10-15
CA2478833C (en) 2015-11-10
WO2003100033A3 (en) 2004-07-15
RS52488B (en) 2013-02-28
EA011853B1 (ru) 2009-06-30
US8153126B2 (en) 2012-04-10
MY154009A (en) 2015-04-30
US7465449B2 (en) 2008-12-16
US20150140609A1 (en) 2015-05-21
IL225633B (en) 2021-12-01
EP2287199A2 (en) 2011-02-23
US9745376B2 (en) 2017-08-29
CL2010000786A1 (es) 2011-02-18
KR20040095281A (ko) 2004-11-12
EP2287199B1 (en) 2017-08-02
JP2013014592A (ja) 2013-01-24
JP2009100763A (ja) 2009-05-14
US20050255102A1 (en) 2005-11-17
IS7443A (is) 2004-09-09
RS80704A (en) 2006-12-15

Similar Documents

Publication Publication Date Title
CL2010000790A1 (es) Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03).
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
AR035581A1 (es) Anticuerpos para il-1beta humana
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
CL2016000324A1 (es) Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1.
CL2010000096A1 (es) Anticuerpo monoclonal o una porción que se une al antígeno del mismo que se une a alk-1, molécula de acido nucleico codificante; composición farmaceutica que lo comprende; uso de dicho anticuerpo para preparar un medicamento útil para inhibir la angiogénesis en un mamifero. (div.sol.2333-06).
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
ECSP066432A (es) Moléculas de enlace terapéuticas
PE20060418A1 (es) Anticuerpos antagonistas de il-17
RS52860B (en) ANTI-ILT7 ANTITELO
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
PE20130159A1 (es) Anticuerpos anti-cd40
RS53058B (en) SP35 ANTIBODIES AND THEIR APPLICATIONS
AR084315A1 (es) Anticuerpos anti-notch1
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
CO5631451A2 (es) Anticuerpo especifico para cd22 humano y composicion farmaceutica derivada
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
CO6251370A2 (es) Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma